Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Instem Plc | INS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 830.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 830.00 |
| Top Posts |
|---|
Posted at 15/8/2023 13:46 by km18 Instem plc issued a solid trading update for H1 2023 indicating that revenue is expected to be around £29.7m, an increase of approximately 10.2%. The Group's balance sheet remains strong, closing cash at 30 June 2023 was £8.4m. With an increasing number of customer touch points and cross selling opportunities management is confident that Instem's performance will be broadly in line with the Board's expectations for the full year. Consensus expectations are for revenues of £65.5m and statutory net profit of £7.2m, growth of 11% and 53% respectively. Valuation is average with forward PE ratio of 18.8x and PS ratio at 2.4x both mid third for the Software & IT Services sector. The share price is in a longer run consolidation phase and lacks momentum for the time being. INS is a solid growth niche Software name at a decent price, but it is a share to monitor for the time being......from WealthOracle |
Posted at 15/5/2023 21:28 by elrico Adjusted EBITDA loss and net cash outflow resulting from its buy-and-build acquisitions have had an impact on 2022. Investors should focus on what INS has built with accretive acquisitions. |
Posted at 21/2/2022 17:22 by km18 ...from last year...Company overview: Instem plc is a major supplier of technology and services for the healthcare sector. The company is working with 600 clients providing them with shorter R&D cycles, better management controls, effective resource utilization and increased regulatory compliance. INS prides itself with 98% client retention rate and they strive to be not simply a provider of services but a strategic partner to their clients. The limited number of acquisitions mean the balance sheet is light on intangibles and growth is based on a blended approach. fundamentally the company is strong. Revenue is growing at 11.6% CAGR and “normalised&rd The interim results are showing good performance. Total revenue is up by 41% to £19.8m, of which recurring is £9.9m. PBT is actually below the H1 2020 at £1.2m, leading to lower EPS as well, due to amortisation of intangibles from acquisitions. The company is enjoying continuous transition to the SaaS model which is increasing the visibility of earnings.... ...from WealthOracleAM |
Posted at 03/9/2021 19:44 by mw8156 good deal of consolidation going on in drug development software, INS having acquired the smaller Swiss competitor and Certara having acquired Pinnacle 21 in the USA. |
Posted at 30/3/2021 14:56 by jombaston I don't think there are any in the UK, not listed anyway. Phil Reason mentioned a company called Cetara which is NASDAQ listed. They have a $3.9bn mkt cap which is 14x their projected 2021 sales. Instem mkt cap of £133m is 2.7x 2021E revenue. EV/EBITDA Cetara is 38.2x whereas INS is 14.4x.Their products are more complements than substitutes even though they operate in the same field and obviously you would expect NASDAQ companies to be rated more highly because, er, well, they just are! |
Posted at 09/3/2020 18:15 by p1nkfish I can't see this virus being negative for INS.What am I missing? |
Posted at 25/10/2019 13:23 by tomps2 Here's the Instem investor presentation by Phil Reason, CEO. Given at the piworld-Progressive Equity Research event in September. Phil was over for the H1 19 results, (normally he's in the US).A very comprehensive overview of the different parts of the business, and a positive outlook. |
Posted at 15/7/2019 06:33 by p1nkfish Very healthy TU.A good way to take advantage of bio-tech without being exposed to front-line approval risk but taking advantage of that risk by helping make it easier to document. Good on all product fronts at INS including AI mention. |
Posted at 01/4/2019 20:07 by newtothisgame3 #INS #Instem eyes further growth following upbeat results |
Posted at 23/7/2018 06:16 by slopsjon2 Trading UpdateResults in-line with management expectations SEND contract value in H1 2018 exceeds that for the entire FY2017 Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces a trading update for the six months to 30 June 2018 (the "Period"). Financial Highlights Trading for the Period was in-line with management expectations. Net cash as at 30 June 2018 was GBP3.7m (30 June 2017; GBP1.2m). Operational Highlights There were positive contributions in most areas, with several significant new client wins in addition to existing customers extending and expanding their adoption of Instem's products and services. Investment in Instem's early phase clinical product, Alphadas, was increased with a focus on current client needs and recognising that the enhancements will have wider market appeal going forward. Importantly, the business continued to expand its SaaS delivery model for accessing its solutions via the Instem Cloud with both Provantis(R) and Samarind RMS being deployed via Software-as-a-Servic SEND Market Update The Regulatory Solutions business performed particularly strongly during the period following the latest FDA mandate of the Standard for the Exchange of Non-clinical Data ("SEND"). Increasing Number of Contract Wins Orders for the Company's SEND software solutions and technology-enabled SEND out-sourced services over the period have increased year-on-year with 103 orders won during the six-month period ended 30 June 2018, compared to 47 and 65 for the first and second six-month periods of 2017 respectively. Importantly, more SEND out-sourced services deals were closed in the first half of 2018 than for the entire 2017 financial year. These contract wins will increasingly impact overall Group revenues in H2 and beyond in line with recruitment of the necessary services personnel, which has been ongoing throughout 2018. These new orders came from 50 unique clients during the period, compared with 32 for the equivalent period last year and the Company continues to win the overwhelming majority of all business quoted for. All of Instem's study conversions are performed on a secure, hosted and validated SEND services platform, which is available and supported 24/7 utilising Instem's submit(TM) SEND software suite. This is the same submit(TM) software that is in production use at pharma and contract research organisations worldwide. Increasing Contract Value The total contracted value of SEND-related new business for the current period increased approximately 190% over the corresponding period last year with outsourced services orders particularly strong. Increasing Pipeline The Company continues to believe that this rapid growth has been largely driven by the IND ('Investigational New Drug') legislation from the FDA, which mandated that studies started after 17 December 2017 and included in IND regulatory submissions must use the electronic SEND format. Future demand appears to be similarly robust and the Company has a strong SEND new business pipeline for both technology and service related sales, with both the number and value of SEND contracts expected to increase in the second half of 2018 and expected to be significantly ahead of last year. Outlook The further shift towards a SaaS based revenue model, combined with increasingly material recurring outsourced services revenue, will see a continued improvement of earnings visibility. This helps position the Company strongly to meet management's full year expectations. Phil Reason, CEO of Instem plc, commented: "The financial year has started well and we are confident further new business, the delivery of recent contract wins and strong operational management will ensure we meet our expectations for the full year." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
